Original ArticlesAntipsychotic Properties of the Partial Dopamine Agonist (−)-3-(3-Hydroxyphenyl)-N-n-Propylpiperidine (Preclamol) in Schizophrenia
Introduction
In laboratory experiments, dopamine agonists have been shown to reduce the synthesis and release of dopamine from dopamine-containing midbrain neurons in experimental animals, presumably through an agonist action at the dopamine autoreceptor (Kehr et al 1972; Bunney et al 1973; Walters and Roth 1975; Walters et al 1975). Moreover, at low doses, dopamine agonists appear to preferentially stimulate the autoreceptor because of the higher sensitivity of this receptor for dopamine and its agonists (Carlsson 1975; Roth 1979). This results in a paradoxical antidopaminergic action of dopamine agonists (Walters and Roth 1976; Skirboll et al 1979). This preclinical action serves as the theoretical basis for evaluating the antipsychotic action of dopamine agonists in schizophrenia, despite the known therapeutic action of dopamine D2 receptor antagonists in psychosis (Delay and Deniker 1952; Klein and Davis 1969). Based on this preclinical rationale, apomorphine was first tested in schizophrenia (Smith et al 1977; Tamminga et al 1978; Corsini et al 1977, Corsini et al 1981; Jeste et al 1983) as was N-propylnorapomorphine (Tamminga et al 1986), and demonstrated to have an antipsychotic effect. Although these agonist treatments showed antipsychotic activity, several other agonist studies, in different designs usually involving chronic treatment, failed to confirm a dopamine agonist-induced antipsychotic effect (Tamminga and Schaffer 1979; Angrist et al 1980; Ferrier et al 1984; Levy et al 1984). These conflicting findings signaled the need to reexamine this strategy. Meanwhile, partial dopamine agonists with their reduced intrinsic activity and even higher preferential affinity for the autoreceptor were synthesized, seemingly even better designed to test this hypothesis. Because the partial dopamine agonist (−)-3-(3-hydroxyphenyl)-N-n-propylpiperidine [(−)-3PPP; Preclamol] was already extensively characterized preclinically, we selected this compound to test for efficacy in schizophrenic persons with florid psychosis.
3PPP is a phenylpiperidine derivative and a dopamine congener. It exists as a racemic mixture with each enantiomer showing different, sometimes opposite, effects at the dopamine synapse (Hjorth et al 1983). The negative enantiomer (−)-3PPP preferentially stimulates the dopamine autoreceptor, but can function as an agonist at the postsynaptic site as well. (−)-3PPP has little significant affinity for other monoaminergic, or other receptors (Clark et al 1985a), including the D1, serotonin 5-HT1A, and 5-HT2 (R. Lahti, unpublished data); however, its actions appear to be at least partially selective for limbic regions. It reduces open field exploratory behavior in rats following injection into nucleus accumbens, but not into striatum (Svensson and Ahlenius 1983). It reduces locomotor activity in mice, but even at high doses fails to induce catalepsy (Arnt 1983; Hjorth et al 1983). It only partially and never fully reverses the increase in dopamine synthesis produced by gammabutyrolactone (GBL), presumably by its full occupation but only partial agonist activity at the dopamine (DA) autoreceptor (Clark et al 1985a, Clark et al 1985b; Pugsley et al 1995). (−)-3PPP only partially inhibits the firing of DA cells in the central nervous system and this action is fully reversed by haloperidol (Clark et al 1985a; Meltzer et al 1995). With the developing concept of partial receptor agonists (Ariens 1983; Kenakin 1993), (−)-3PPP became the first partial dopamine agonist widely evaluated pharmacologically for its effects on dopamine system function (Bergstrom et al 1986). Based on the receptor state binding affinity ratio method or the inhibition of cyclic adenosine monophosphate (AMP) to determine intrinsic activity, (−)-3PPP has an intrinsic activity at the D2 receptor of 35%, at the D3 receptor of 44%, and at the D4 receptor of 83% (Lahti et al 1992, Lahti et al 1996; Chio et al 1994). In Phase I human safety studies carried out in schizophrenic individuals, the use of (−)-3PPP has been shown to be safe, its single dose kinetics defined, and the presence of efficacy suggested (Tamminga et al 1992).
We report here the results of two sequential double-blind, placebo-controlled studies of (−)-3PPP in neuroleptic-free schizophrenic patients, one a preliminary dose-finding study and the other, an early efficacy trial.
Section snippets
Patients and Diagnosis
Sixteen patient volunteers with schizophrenia agreed to participate in these two studies after being informed about the nature of the research. The protocol and consent form were reviewed and approved by the University of Maryland Human Volunteer Board. Subjects were inpatients at the Maryland Psychiatric Research Center (MPRC), Residential Research Unit for the duration of the study. They received a diagnosis of schizophrenia using DSM-III-R criteria as made by two experienced clinicians based
Preliminary Dose-Finding Study
This initial study was conducted as a 6-week drug–placebo crossover with multiple doses tested in the drug phase. Regardless of dose, during the first week of treatment with (−)-3PPP the overall mean BPRS total score decreased by 14% compared to placebo treatment in the 9 patients studied; however, after that in the second and third weeks, the total BPRS score changed less than 5% from placebo with the (−)-3PPP treatment (Fig. 1). This was true for both positive and negative symptoms. Because
Discussion
We report here that in otherwise drug-free schizophrenic persons, the partial dopamine agonist (−)-3PPP has a significant antipsychotic effect, acting on both the positive and negative symptoms of the illness, without the appearance of any motor side effects. The two consecutive studies presented here are an initial part of an effort to characterize the action of the partial dopamine agonist (−)-3PPP in schizophrenic psychosis. We have previously reported a phase I safety study in schizophrenic
Acknowledgements
This research was supported by NIMH grant #MH49667 and #MH40279.
The authors wish to thank the staff of the Residential Research Unit of the Maryland Psychiatric Research Center, Deborah Medoff and Li-Wan Chen for statistical consultation, and Kristin Ricasa for secretarial assistance.
References (53)
Differential behavioral effects of dopamine agonists in developing ratsA study of (−)-3PPP enantioners
Eur J Pharmacol
(1983)- et al.
Differential electrophysiological effects of (−)-3PPP and its enantioners on dopamine autoreceptors and postsynaptic receptors
Eur J Pharmacol
(1986) - et al.
Bromocriptine therapy in chronic schizophreniaEffects on symptomatology, sleep patterns, and prolactin response to stimulation
Psychiatry Res
(1983) - et al.
The Maryland Psychiatric Research Center scale and the characterization of involuntary movements
Psychiatry Res
(1997) - et al.
Apomorphine response and subtyping of schizophrenia
Prog Neuropsychopharmacol Biol Psychiatry
(1983) - et al.
The schedule for the deficit syndromeAn instrument for research in schizophrenia
Psychiatry Res
(1989) - et al.
Affinities and intrinsic activities of dopamine receptor agonists for the hD21 and hD4.4 receptors
Eur J Pharmacol
(1996) - et al.
B-HT 920, a dopamine D2 agonist in the treatment of negative symptoms of chronic schizophrenia
Biol Psychiatry
(1993) - et al.
A partial dopamine agonist SDZHDC912 has antipsychotic efficacy. Sandoz Collaborating Centers [abstract]
Schizophr Res
(1993) - et al.
Suppression of exploratory activity in the rat by the local application of 3-PPP enantiomers into nucleus accumbens
European Journal of Pharmacology
(1983)
Negative symptoms of schizophreniaDefinitions and reliability
Arch Gen Psychiatry
Responses to apomorphine, amphetamine and neuroleptics in schizophrenic subjects
Psychopharmacology
Intrinsic activityPartial agonists and partial antagonists
J Cardiovasc Pharmacol
A checklist for the diagnosis of schizophrenia
Br J Psychiatry
Comparison of effects of L-dopa, amphetamine, and apomorphine on firing rate of rat dopaminergic neurons
Nature
Measurement of premorbid adjustment in chronic schizophrenia
Schizophr Bull
Dopaminergic autoreceptors
Activation of heterologously expressed D3 dopamine receptorsComparison with D2 dopamine receptors
Mol Pharmacol
Dopamine-receptor agonistsMechanisms underlying autoreceptor selectivity: I. Review of the evidence
J Neural Transm
Dopamine-receptor agonistsMechanisms underlying autoreceptor selectivity: II. Theoretical considerations
J Neural Transm
Sedative, hypnotic and antipsychotic effects of low doses of apomorphine in man
Adv Biochem Psychopharmacol
Behavioral effects of apomorphine in manDopamine receptor implications
Clinical effects of apomorphine in schizophrenia
Br J Psychiatry
Central dopamine receptor agonist and antagonist actions of the enantiomers of (−)-3PPP
Psychopharmacology
Integrating incidence and prevalence of tardive dyskinesia
Psychopharmacol Bull
Cited by (103)
Dopamine partial agonists and prodopaminergic drugs for schizophrenia: Systematic review and meta-analysis of randomized controlled trials
2022, Neuroscience and Biobehavioral ReviewsCitation Excerpt :We attempted to obtain these data, but received a response from only one corresponding author to inform us that the study was ongoing (Euctr, 2014). We included 30 trials of dopamine partial agonists; thirteen studies of aripiprazole (three of aripiprazole IM (Kane et al., 2014; Kane et al., 2012; Meltzer et al., 2015), ten of aripiprazole PO (Petrie et al., 1997; Daniel et al., 2000; Kane et al., 2002; Cutler et al., 2006; McEvoy et al., 2007; Pigott et al., 2003; Potkin et al., 2003; Cantillon et al., 2017; Durgam et al., 2015; Euctr, 2009)), six of brexpiprazole (Euctr, 2009; Correll et al., 1 2015; Fleischhacker et al., 1 2017; Ishigooka et al., 2018; Kane et al., 2015; Nct, 2013), five of cariprazine (Durgam et al., 2015; Durgam et al., 2016; Durgam et al., 2016; Durgam et al., 2014; Kane et al., 2015), four of bifeprunox (Bourin et al., 2007 Mar; Casey et al., 2008; Euctr, 2008; Meltzer et al., 2007) and one study each of preclamol (Lahti et al., 1998) and brilaroxazine (Cantillon et al., 2017). We included 29 trials of prodopaminergic treatments; eight studies of modafinil (Arbabi et al., 2012; Freudenreich et al., 2009; Lohr et al., 2013; Michalopoulou et al., 2015; Minzenberg et al., 2016; Pierre et al., 2007; Sevy et al., 2005; Shoja Shafti and Akbari, 2016), three studies of armodafinil (Bobo et al., 2011; Kane et al., 2010; Kane et al., 2012), five studies of dexamphetamine and lisdexamphetamine (Barch and Carter, 1 2005; Lasser et al., 2013; Martin et al., 2014; Pietrzak et al., 2010; Sanfilipo et al., 1996; Strakowski et al., 1 1997), three studies each of L-dopa (Chouinard et al., 1987; Gerlach and Luhdorf, 1975; Owens et al., 1994) and apomorphine/N-propylnorapomorphine (Schaffer et al., 1980; Tamminga et al., 1986; Syvalahti et al., 1986), two studies each of bromocriptine(Gattaz et al., 1989; Tamminga and Schaffer, 1979) and methylphenidate(Lieberman et al., 1994; Carpenter et al., 1992), and one study each of pramipexole (Kelleher et al., 2012), tolcapone (Nct, 2002) and the ergot dopamine agonist CF-25–397 (Tamminga and Schaffer, 1979).
Dopamine receptors in emesis: Molecular mechanisms and potential therapeutic function
2020, Pharmacological ResearchStereoselective synthesis of (−)-3-PPP through palladium-catalysed unactivated C(sp<sup>3</sup>)–H arylation at the C-3 position of L-pipecolinic acid
2017, Tetrahedron LettersCitation Excerpt :The most potent therapeutically active compounds for central dopamine autoreceptor stimulating activity is (−)-3-(3-hydroxyphenyl)-N-(n-propyl)-piperidine [(−)-3-PPP, Preclamol],1–8 which is also reported to be the first selective D2-like dopamine autoreceptor agonist.7,8 In addition, preclamol was tested for antipsychotic potential with therapeutic effect in the treatment of schizophrenia and Parkinson’s diseases.9–11 Furthermore, preclamol has been extensively studied as a pharmacological tool to investigate dopaminergic mechanisms (Fig. 1).12–15
Partial agonists in schizophrenia-why some work and others do not: Insights from preclinical animal models
2011, International Journal of Neuropsychopharmacology